ADA recommends metformin as the preferred drug treatment for type 2 diabetes

The American Diabetes Association (ADA) recommends metformin as the first-line treatment for type 2 diabetes. Metformin monotherapy should be initiated at the time of diagnosis for most patients unless there are contraindications. A synopsis of the ADA's recommendations on pharmacologic approaches to glycemic treatment of type 2 diabetes is published in Annals of Internal Medicine.

The evidence suggests that metformin is effective, safe, and inexpensive and may reduce the risk for cardiovascular events and death in patients with diabetes. However, if the patient does not tolerate or has contraindications to metformin, another option should be considered. For patients with an HbA1c level of 9 percent or greater who are not acutely symptomatic, initiation of dual combination therapy should be considered to more quickly achieve the target HbA1c level. If the patient has a random glucose level of 16.7 mmol/L or greater or an HbA1c level of 10 percent or greater and has acute symptoms of polyuria, polydipsia, or weight loss, combination therapy that includes should be considered.

Providers should assess whether the HbA1c target has been achieved within approximately 3 months of therapy initiation. If not, therapy should be intensified.

When or if patients need , a safe and simple approach is to prescribe patients 10 units of per day and increase the dose by 10 percent to 15 percent once or twice weekly until the fasting blood glucose target is met. Insulin is typically used with metformin and sometimes one additional non-insulin agent. If target HbA1c level is still not met, there are several other insulin products that can be considered, including concentrated insulin products, inhaled insulin, and combination injectable . Physicians should use a patient-based approach and refer to the ADA's recommendation chart to help determine which regimen is best.


Explore further

Exenatide, pioglitazone effective for poorly controlled T2DM

More information: Annals of Internal Medicine, http://annals.org/aim/article/doi/10.7326/M16-2937
Journal information: Annals of Internal Medicine

Citation: ADA recommends metformin as the preferred drug treatment for type 2 diabetes (2017, March 13) retrieved 18 January 2020 from https://medicalxpress.com/news/2017-03-ada-metformin-drug-treatment-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments